 
    Overview
Background
Dr Jodi Saunus is a senior fellow who specialises in translational research on metastatic breast cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research in 2022 to help facilitate patient-focused research at the interface of biomedical R&D and clinical practice.
Dr Saunus has an honours degree in biochemistry and biomedical science, a PhD in breast cancer molecular genetics, and broad post-doctoral experience in immunology, molecular cell biology, pathology informatics, and early-phase investigator-initiated clinical trials. Her current portfolio focuses finding new ways to improve the clinical management of aggressive breast cancer, with a focus on triple-negative breast cancer, and the prevention and treatment of brain metastases. This work spans across multiple disciplines and capabilities, and broadly involves:
- Molecular profiling of patient-donated blood and tumour tissue samples to identify features that can predict treatment response, or represent previously uncharacterised therapeutic targets.
- Using experimental models of breast cancer metastasis to learn about the molecular mechanisms exploited by cancer cells to survive and grow in brain tissue.
- Developing innovative treatment strategies that work differently to conventional cancer drugs, including alpha-particle endoradiotherapy and in-situ vaccination.
With an outstanding network of collaborators from academia and clinical practice, she has secured more than $6M to fund this work and has a track record of publishing in prominent biomedical research journals (e.g., Cancer Research, Nature, Science Translational Medicine, Nature Communications and The Journal of Pathology).
Peripherally, Jodi is a strong proponent of biospecimen banking, and clinician and consumer engagement in translational research.
Availability
- Dr Jodi Saunus is:
- Not available for supervision
- Media expert
Fields of research
Qualifications
- Doctor of Philosophy, The University of Queensland
Research interests
- 
Biomarkers of triple-negative breast cancer progression and response to therapyUsing published datasets, and tissue donated by Brisbane breast cancer patients, we're trying to identify new biomarkers of prognosis and treatment response in breast cancer. 
- 
Understanding how the triple-negative breast cancer transcriptome is rewired during tumour progressionWe apply mathematical approaches to analyse transcriptional networks in TNBC, illuminating how cell biology evolves during tumour development and post-treatment relapse. 
- 
Understanding the brain metastasis immune microenvironmentIn collaboration with immuno-oncology experts at the Peter MacCallum Cancer Centre in Melbourne, we are studying the expression of common tumour antigens to develop strategies for vaccination against cancer. 
- 
Therapeutic antibody uptake in brain metastasesBrain metastases are broadly refractory to existing systemic therapies. We believe that abnormal vascular function and interstitial fluid dynamics in these tumours may contribute more than previously appreciated. We aim to engineer molecular-targeted carriers that improve the effectiveness and reduce the side-effects of radiotherapy and chemotherapy. 
Funding
Current funding
Supervision
Availability
- Dr Jodi Saunus is:
- Not available for supervision
Supervision history
Current supervision
-               
Doctor Philosophy Epigenomic determinants of chemotherapy response in triple-negative breast cancerPrincipal Advisor Other advisors: Professor Chris Pyke, Associate Professor Adam Ewing 
-               
Master Philosophy Treatment patterns and prognostic indicators in triple-negative breast cancer: a multicentre study of contemporary cases from Queensland, AustraliaPrincipal Advisor Other advisors: Professor Chris Pyke 
-               
Doctor Philosophy Investigating the diagnostic and functional significance of specific epigenomic features in triple-negative breast cancer (TNBC)Principal Advisor Other advisors: Honorary Professor Kum Kum Khanna 
-               
Master Philosophy Development and characterization of bispecific and bivalent nanobodies for targeting ErBb receptorsAssociate Advisor Other advisors: Dr Nick Fletcher, Dr Pie Huda, Professor Kristofer Thurecht 
-               
Doctor Philosophy Strategies to improve immunotherapy for patients with glioblastoma or breast cancer brain metastasesAssociate Advisor Other advisors: Professor Fiona Simpson, Professor Nikolas Haass 
-               
Doctor Philosophy Triple-negative breast cancer in Australia: investigating factors associated with prognosisAssociate Advisor Other advisors: Dr Melinda Protani, Dr Louise Marquart-Wilson 
-               
Doctor Philosophy Applying long-read sequencing technologies to cancer genomesAssociate Advisor Other advisors: Dr Yuanhao Yang, Dr Sandra Richardson, Associate Professor Adam Ewing 
Completed supervision
-               
2022 Doctor Philosophy Investigation of epigenetic influences on DNA methylation in Triple Negative Breast CancerPrincipal Advisor Other advisors: Professor Melissa Brown, Professor Sunil Lakhani 
-               
2022 Doctor Philosophy Development of theranostic nanomedicines for breast cancer brain metastasesPrincipal Advisor Other advisors: Professor Sunil Lakhani 
-               
2021 Doctor Philosophy Detailed Characterisation of Metaplastic Breast CarcinomaAssociate Advisor Other advisors: Professor Sunil Lakhani, Associate Professor Amy McCart Reed 
-               
2016 Doctor Philosophy Identification of new prognostic biomarker for triple negative breast cancerAssociate Advisor Other advisors: Professor Sunil Lakhani, Associate Professor Peter Simpson 
-               
2015 Doctor Philosophy Heregulin/HER3 signalling increases invasive behaviour of HER2-positive breast cancer cellsAssociate Advisor Other advisors: Professor Sunil Lakhani 
Media
Enquiries
Contact Dr Jodi Saunus directly for media enquiries about:
- brain metastases
- breast cancer
- metastatic breast cancer
- stage IV breast cancer
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: